Stay updated on Tipifarnib and Alpelisib in R/M HNSCC Clinical Trial
Sign up to get notified when there's something new on the Tipifarnib and Alpelisib in R/M HNSCC Clinical Trial page.

Latest updates to the Tipifarnib and Alpelisib in R/M HNSCC Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check10 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check17 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check24 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.3%
- Check46 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check61 days agoChange DetectedThe page has undergone significant content removal, particularly regarding a clinical trial for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), including detailed descriptions of the trial's purpose, inclusion and exclusion criteria, and the previous version number. The new version introduces a new revision number but lacks the critical information about the trial.SummaryDifference17%
Stay in the know with updates to Tipifarnib and Alpelisib in R/M HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tipifarnib and Alpelisib in R/M HNSCC Clinical Trial page.